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Abstract
Chronic kidney disease and associated comorbidities (diabetes, cardiovascular dis-
eases) manifest with an accelerated ageing phenotype, leading ultimately to organ fail-
ure and renal replacement therapy. This process can be modulated by epigenetic and
environmental factors which promote loss of physiological function and resilience to
stress earlier, linking biological age with adverse outcomes post‐transplantation includ-
ing delayed graft function (DGF). The molecular features underpinning this have yet to
be fully elucidated. We have determined a molecular signature for loss of resilience
and impaired physiological function, via a synchronous genome, transcriptome and
proteome snapshot, using human renal allografts as a source of healthy tissue as an
in vivo model of ageing in humans. This comprises 42 specific transcripts, related
through IFNγ signalling, which in allografts displaying clinically impaired physiological
function (DGF) exhibited a greater magnitude of change in transcriptional amplitude
and elevated expression of noncoding RNAs and pseudogenes, consistent with
increased allostatic load. This was accompanied by increased DNA methylation within
the promoter and intragenic regions of the DGF panel in preperfusion allografts with
immediate graft function. Pathway analysis indicated that an inability to sufficiently
resolve inflammatory responses was enabled by decreased resilience to stress and
resulted in impaired physiological function in biologically older allografts. Cross‐com-
parison with publically available data sets for renal pathologies identified significant
transcriptional commonality for over 20 DGF transcripts. Our data are clinically rele-
vant and important, as they provide a clear molecular signature for the burden of “wear
and tear”within the kidney and thus age‐related physiological capability and resilience.
Abbreviations: ABCA8, ATP‐binding cassette subfamily A member 8; ACKR3, atypical chemokine receptor 3; BTN3A2, butyrophilin subfamily 3 member A2; CCL19, C‐C motif chemokine
ligand 19; CHGB, chromogranin B; CXCL10, C‐X‐C motif chemokine ligand 10; CYP17A1, cytochrome P450 family 17 subfamily A member 1; dsRNA, double‐stranded RNA; eIF2, eukaryotic
initiation factor 2 signalling, protein ubiquitination; eIF4, eukaryotic initiation factor 4; FCGR1C, Fc fragment of IgG receptor Ic/CD64; FCGR2C, Fc fragment of IgG receptor IIc/CD32; FCRL3,
Fc receptor‐like 3; GABBR1, gamma‐aminobutyric acid type B receptor subunit 1; HMGB1, high‐mobility group protein B1; HSPB7, heat‐shock protein family B (small) member 7; IFI44L,
interferon‐induced protein 44‐like; ING, interferon gamma; KLRB1, killer cell lectin‐like receptor B1; LMO7, LIM domain 7; LPGAT1, lysophosphatidylglycerol acyltransferase 1; MMP9, matrix
metallopeptidase 9; mTOR, mechanistic target of rapamycin; NLRC4, NLR family, CARD domain‐containing 4; NLRP2, NLR family, pyrin domain‐containing 2; OAS2, 2'‐5'‐oligoadenylate
synthetase 2; p70Sk6, ribosomal protein S6 kinase beta‐1; PTPRC, protein tyrosine phosphatase, receptor type C; RAP1GAP, RAP1GTPase‐activating protein; REG1B, regenerating family
member 1 beta; RRAGD, Ras‐related GTP‐binding D; SEMA3A, semaphorin 3A; SULT1E1, sulfotransferase family 1E member 1; TAGAP, T‐cell‐activation RhoGTPase‐activating protein; TLR4,
Toll‐like receptor 4; TREM1, triggering receptor expressed on myeloid cells‐1; UBD, ubiquitin D; ZNF676, zinc finger protein 676.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Received: 6 February 2018 | Revised: 8 June 2018 | Accepted: 2 July 2018
DOI: 10.1111/acel.12825
Aging Cell. 2018;17:e12825.
https://doi.org/10.1111/acel.12825
wileyonlinelibrary.com/journal/acel | 1 of 16
Suhaib Mohammed, The European
Bioinformatics Institute (EMBL‐EBI), Saffron
Walden, UK.
Laura Monaghan, Paul O'Gorman Leukaemia
Research Centre, Gartnavel General
Hospital, Glasgow, UK.
Funding information
This research was funded via a
collabora0074ive research award from
GlaxoSmithKline to PGS.
1 | INTRODUCTION
The changing demographics of age in human society is anticipated
to result in a major burden of age‐related morbidities, as improve-
ments in health span have failed to match the increase in average
global lifespan. Notably, deaths due to chronic kidney disease have
increased globally, despite significant decline in other aetiologies
(Christopher & Murray, 2015). This is pertinent to researchers inves-
tigating ageing, as accelerated cellular and physiological ageing are
underlying components of renal dysfunction (Kooman, Kotanko,
Schols, Shiels, & Stenvinkel, 2014; McGlynn et al., 2009; Schmitt,
Susnik, & Melk, 2015), where systemic differences are layered on
top of the dysregulated ageing process and patients show a higher
incidence of mortality in comparison to healthy chronologically age‐
matched individuals. As the prevalence of CKD parallels an increased
prevalence in type 2 diabetes, obesity and a sedentary lifestyle
(Stengel, Tarver‐Carr, Powe, Eberhardt, & Brancati, 2003), an allo-
static outcome reflecting the “burden of life style” may be present
next to the renal dysfunction.
Allostatic load can be defined as a composite indicator of accu-
mulated biological stress over the life course, which predisposes to
morbidity in the face of chronic or repeated stress exposure (Rubin,
2016). It is reflective of the biological age of a tissue organ or organ-
ism, as it directly impacts on age‐related physiological function.
We have previously developed the use of renal allografts as an
in vivo model to study healthy tissue ageing in humans, whose phys-
iological function can be tracked longitudinally to demonstrate that
allograft biological age is more important than chronological age in
prognostication of post‐transplant allograft performance (Gingell‐Lit-
tlejohn et al., 2013; McGuinness et al., 2016).
One testable prediction following this demonstration is that
organs with increased biological age should reflect the cumulative
burden of “wear and tear” and thus be less resilient to transplant‐re-
lated stresses and display reduced physiological function as a conse-
quence. Assessing the related changes in molecular biology in these
renal allografts is not straightforward (Shiels, McGuinness, Eriksson,
Kooman, & Stenvinkel, 2017). To do so, we have used an analysis of
a notable clinically relevant allograft phenotype displaying impaired
physiological function, termed delayed graft function (DGF), to
determine whether organs showing DGF are less resilient than those
undergoing immediate graft function (IGF). Additionally, we have
determined whether features associated with lack of physiological
resilience were reflected in the pretransplant transcriptomes of
respective organs.
A higher incidence of DGF has been associated with the use of
allografts from older extended criteria donors (ECD, age >60, or >50
with two of the following: a history of high blood pressure, a crea-
tinine ≥1.5, or death resulting from a stroke), donation after cardiac
death donors (DCD) and increased allograft biological age (Mallon,
Summers, Bradley, & Pettigrew, 2015; McGuinness et al., 2016;
Menke, Sollinger, Schamberger, Heemann, & Lutz, 2014; Mundt,
Yard, Kramer, Benck, & Schnulle, 2015; Schroppel & Legendre,
2014). The extent to which donor and recipient‐related characteris-
tics influence the magnitude of IRI and/or DGF occurrence, beyond
accepted clinical risk factors for DGF, remains to be proven (Menke
et al., 2014; Mundt et al., 2015; Schroppel & Legendre, 2014), par-
ticularly in the context of allograft repair, or regeneration pathways,
activated in response to IRI. Increased demand for organ donation,
coupled with increasing chronological age and associated comorbidi-
ties in the donor population, has necessitated the use of organs that
have been previously deemed as marginal for clinical use (Morrissey
& Monaco, 2014; Nagaraja et al., 2015).
DGF has also proven refractory to modelling both in vitro and
in preclinical model organism studies. This study aimed to identify
a human‐specific molecular signature associated with DGF and to
enable adjustment for the effects of IRI‐related molecular changes,
in the absence of model systems for analysis of DGF mechanisms,
as well as providing direct insight into its manifestation. Addition-
ally, this strategy was designed, to enable the validation of any
DGF‐associated signature, by comparison with existing publically
available renal data sets, in order to elucidate whether there were
common underpinning molecular processes in their manifestation
and whether these reflected the burden of “wear and tear” in the
kidney. We selected a very closely matched clinical cohort based
on age, gender, length of ischaemic time and low HLA mismatch.
These were divided into two groups based on recovery of organ
function after transplantation, with emphasis on extreme functional
differences, namely either DGF or IGF (Table1). An extreme DGF
phenotype was defined as (a) the need for dialysis within 7 days of
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TABLE 1 Patient clinical and experimental characteristics for the RNAseq cohort (top panel) and combined cohort (bottom panel)
RNAseq cohort (n = 23)
DGF (n = 11) IGF (n = 12)
Variable
Mean (Min‐Max)/
Proportion
Standard deviation
(if applicable)
Mean (Min‐Max)/
Proportion
Standard deviation
(if applicable)
Donor gender (males/females) 6/5 5/7
Donor age (years) 55 (40–74) 17.6 53.2 (40–77) 10.7
Donor serum creatinine at retrieval (µmol/L) 73.25 (44–125) 26.6 78.64 (41–125) 25.6
Donor type
DBD/DCD 7/4 9/3
ECD 6 4
DBD‐ECD 4 3
DCD‐ECD 2 1
Cause of death
Intracranial haemorrhage 7 8
Hypoxic brain injury 0 2
Trauma 0 2
Cardiac arrest 1 0
Intracranial thrombus 1 0
Respiratory failure 1 0
Meningitis 1 0
Recipient gender (males/females) 8/3 8/4
Recipient age (years) 57.9 (42–72) 10.1 51.1 (35–70) 10.1
Previous transplantation 0 0
HLA Mismatch
HLA‐A (0/1/2) 4/5/2 4/6/1
HLA‐B (0/1/2) 2/9/0 3/7/1
HLA‐DR (0/1/2) 4/7/0 3/7/0
Cold ischaemic time (hr) 12.1 (9–17) 2.8 11.1 (6–20) 4.5
Warm ischaemic time (min) 29.3 (21–40) 6.1 31.3 (22–40) 6.7
T1/2 from 4 to 21 days less than 3 days
Serum creatinine level at 6 months (µmol/L) 126.7 (89–158) 2.1 104.4 (84–166) 1.74
Combined patient cohort (N = 55) Mean (Min‐Max)/Proportion Standard deviation (if applicable)
Donor gender (males/females) 33/22
Donor age (years) 50.5 (11–77) 16.4
Donor serum creatinine at retrieval (µmol/L) 87.1 (41–195) 35.7
Ethnicity (Caucasian: Asian) 54:1
Donor type
DBD/DCD 37/11
ECD 34
DBD‐ECD 16
DCD‐ECD 5
Cause of death
Intracranial haemorrhage 35
Hypoxic brain injury 10
Trauma 7
Cardiac arrest 1
Intracranial thrombus 1
Respiratory failure 1
(Continues)
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transplantation, with the exception of hyperkalaemia on the first
postoperative day, and (b) the failure of serum creatinine to reduce
by 50% within the first week, which is indicative of poor recovery
of renal function (Figure 1a; Aitken et al., 2015). IGF was defined
as reduction in serum creatinine by 50% in less than 3 days post‐
transplantation. Additionally, we undertook a retrospective analysis
of paired allograft biopsies from this cohort, obtained at two time
points: preimplantation during the preparatory phase (preperfusion)
and after allograft reperfusion when circulation was restored (post-
perfusion).
TABLE 1 (Continued)
Combined patient cohort (N = 55) Mean (Min‐Max)/Proportion Standard deviation (if applicable)
Meningitis 0
Donor hypotension (N) 39
Donor hypertension (N) 23
Recipient gender (males/females) 32/23
Recipient age (years) 54.2 (27–73) 10.1
Aetiology of Renal Failure
IgA nephropathy 9
Glomerulonephritis 6
APKD 12
Reflux/obstructive uropathy 7
Hypertension 4
Diabetes mellitus 2
Unknown 8
Goodpasture's syndrome 1
Anatomical anomalies 2
Drug related 1
Stone disease 1
HUS 1
FSGS 1
Previous Transplant
0 45
1 7
2 2
HLA Mismatch
HLA‐A (0/1/2) 9/18/10
HLA‐B (0/1/2) 10/23/5
HLA‐DR (0/1/2) 24/10/0
Cold ischaemic time (hr) 12.8 (6–21) 3.9
Immunosuppression
Induction
Basiliximab/campath/ATG 42/6/6
Maintenance
Tacrolimus/Sirol/Cyc 54/0/1
Prednisolone 51
Mycophenolatemofetil 55
BPAR 1
DGF 19
Serum creatinine level at 6 months (µmol/L) 131 (61–523) 74.4
MDRD4 at 6 months (ml min−1 1.73 m−2) 57.4 (9–102) 22.3
Serum creatinine level at 12 months (µmol/L) 137.6 (67–377) 62.8
MDRD4 at 12 months (ml min−1 1.73 m−2) 51.1 (10–89) 20.8
Note. Continuous variables are expressed as mean with standard deviation, whereas categorical variables are expressed as proportions.
4 of 16 | MCGUINNESS ET AL.
We have used this approach to test the hypothesis that DGF is
a manifestation of organ “wear and tear” (i.e. its allostatic load as a
function of its biological age) and that the impaired physiological
capability can be defined using a specific set of molecular features,
independently of allograft damage acquired during the peritransplan-
tation period.
2 | RESULTS
2.1 | RNAseq cohort characteristics are related to
differences associated with DGF and response to
reperfusion injury
Differential gene expression associated with perfusion, or DGF sta-
tus, was assessed alone, or stratified by donor gender (Figure 1b).
Significant variation (28%) was observed between donor genders.
This was more pronounced than the pre‐/postperfusion or DGF/IGF
variance, each of which grouped into distinct gender clusters (Sup-
porting Information Figure S1 in Data S1). The magnitude of change
in pre‐ versus postperfusion biopsies was more pronounced than in
a comparison of DGF versus IGF biopsies (Figure1b, Supporting
Information Figure S2 in Data S1). Hierarchical clustering of the sam-
ples is presented in Figure 1c. 3,893 of 4,052 transcripts were differ-
entially expressed between preperfusion and postperfusion samples
after adjustment for donor gender. Fifty‐five transcripts correlated
uniquely with DGF outcome, and only six of these were significantly
different between DGF and IGF after adjustment for donor gender:
REG1B, GABBR1, UBD, DAZ1, ABCA7 and BTN3A2.
Comparison of whole transcriptional profiles (TOM1) with differ-
ent clinical risk factors for DGF including ECD/SCD, DCD/DBD, cold
(CIT) and warm ischaemia time (WIT) did not reveal any overt tran-
scriptional changes. However, each factor was independently associ-
ated with unique transcript expression (Figure 1d). CDKN2A/p16ink4a
expression correlated with DGF occurrence and long‐term allograft
function post‐transplantation, when used as a composite BioAge (pre-
transplant donor risk classification system using CDKN2A and ECD
criteria) (Gingell‐Littlejohn et al., 2013; McGuinness et al., 2016). No
common targets were associated with BioAge and DGF risk factors.
Eight hundred and eighty‐one transcripts were differentially expressed
between samples with low versus high CDKN2A/p16ink4a expression
(below/above median for sequenced sample set) with 349 being
unique for BioAge. Stratification by BioAge revealed 58 common tar-
gets for DBD/DCD, ECD/SCD and BioAge (Figure 1d).
Further analysis, in conjunction with (a) perfusion status changes
(preperfusion vs. postperfusion, TOM2) and (b) differences between
DGF and IGF transcriptomes (TOM3), established a molecular signa-
ture for DGF adjusted for the effect of reperfusion (DGF‐specific
signature; TOM4).
Forty‐nine transcripts were identified as markers of DGF
(TOM3). However, adjustment for perfusion status (TOM4) reduced
this to 42 differentially expressed transcripts (Supporting Information
Table S1 in Data S2, Figure 2). DGF outcome and donor gender
were related to the DGF‐specific signature, with male and female
donors forming distinct clusters indicative of a donor gender‐driven
DGF phenotype (Figure 2a). Further analysis of DGF‐specific tran-
scripts revealed that overall expression changes in response to reper-
fusion occurred along a similar trajectory in both DGF and IGF, but
the magnitude of this change was greater for those exhibiting DGF.
This suggests that the degree of response to reperfusion injury is
significant in post‐transplant outcome (Supporting Information Fig-
ure S2 in Data S1). Further analysis of the transcriptome for DGF‐
specific signatures independent of IRI, but stratified by BioAge,
revealed the presence of only 22 DGF‐specific targets (Figure 2b).
Analysis of the DGF signature across the age groups (<50; 50–60
and >60) revealed significant changes for NLRC4, IL7R and GRIN3B.
Additional analyses, involving comparison of the allograft
response to IRI (both for DGF and IGF status), using the respective
RNAseq data sets, with publically available data sets for other renal
pathologies, were undertaken to identify additional transcripts. These
were included in further validation testing (Supporting Information
Datas S1 and S3).
2.2 | DGF, immune response generation and
senescence pathways
Initial analysis of the effect of perfusion status on the pathways
associated with senescence revealed 22 transcripts that had been
significantly affected, these included BMI1, CDK2, CDKN1A, ETS2,
RB1, RBL2, p53/Rb signalling (CDKN2B, CITED2, ING1, MYC, PCNA,
PIK3C, SERPINE1, SIRT1, SPARC), interferon‐related (CDKN1A,
EGR1, INFG, IRF7, RB1), IGF1, MAP2K3, PCNA, as well as cell adhe-
sion molecules affected by senescence (COL1A1, COL3A1).
Ingenuity®Pathway Analysis (IPA®, QIAGEN Redwood City; USA)
indicated that DGF was allied with activation of innate immune
responses, including GABA signalling, TREM1 signalling, pattern
recognition receptors and B‐cell development (Supporting Informa-
tion Tables S2–S5 in Data S2). The top ranked networks comprised
immune system activation, cell death/survival, cellular fitness and
cell–cell communication, renal and urological system development
and function. An upstream regulator analysis algorithm also identified
activation of the immune system and cell‐mediated immune
responses in the development of DGF. The main “drivers” within
these processes, typically related to the response to pathogens (bac-
terial and viral), or sterile inflammation and induction of the sec-
ondary INF‐γ‐associated responses to dsRNA, which have been
linked to mechanisms underpinning autoimmune diseases (Brenci-
cova & Diebold, 2013; Nellimarla & Mossman, 2014; Pollard, Cauvi,
Toomey, Morris, & Kono, 2013) and cellular ageing (Gorbunova,
Boeke, Helfand, & Sedivy, 2014).
Further analysis of our data sets, either individually, or in direct
comparison with publicly available data sets, demonstrated overt
links to inflammatory responses, inherent in renal pathologies, and
highlighted the importance of interaction between lymphoid and
nonlymphoid cells in the context of renal function (Supporting Infor-
mation Figures S1–S4 in Data S3). Pathway analysis of differentially
expressed targets relative to perfusion status highlighted pathways
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overlapping with processes inherent in ageing, including eIF2
(eukaryotic initiation factor 2) signalling, protein ubiquitination,
eukaryotic initiation factor 4 (eIF4) and ribosomal protein S6 kinase
beta‐1 (p70Sk6) signalling and interleukin‐17 (IL‐17)‐mediated cyto-
kine regulation (Supporting Information Tables S1–S3 in Data S5).
These data suggest that DGF outcome may be related to a dif-
ferential capacity to restore physiological homeostasis following IRI.
Further analysis of an additional model (DGF pre‐ vs. postperfusion
and IGF pre‐ vs. postperfusion, Model 2) revealed that the transcrip-
tional response to reperfusion injury was similar for allografts, irre-
spective of their post‐transplant outcome. Resolution of transplant‐
related stresses and restoration of physiological homeostasis were,
however, exacerbated in those that manifested DGF (Supporting
Information Tables S5–S10 in Data S5) suggesting, that donor‐organ
resilience to stress may be a key determinant of DGF, which is
congruent with recent findings linking organ function to biological
age (Gingell‐Littlejohn et al., 2013; McGuinness et al., 2016). Signifi-
cantly, this is supported by the observation that the transcriptional
amplitude of change in DGF signature genes following reperfusion
was significantly larger than in IGF. This is consistent with there
being a greater degree of allostatic load in organs developing DGF
and an inability to restore transcriptional and physiological processes
to function within normal physiological parameters as quickly as
organs with IGF.
2.3 | Epigenetic status is linked to DGF and
perfusion status
The effect of IRI on epigenetic status associated with DGF outcome
was analysed in connection with changes in global DNA methylation
F IGURE 1 Description of samples with DGF and IGF occurrence selected for RNAseq. (a) Schematic representation of peritransplantation
period and its relation to DGF and IGF (b) MA plots representing significantly differential gene expression between the two experimental
groups (preperfusion (B) vs. postperfusion (B1) samples and DGF vs. IGF) presented as log2‐fold changes against mean gene expression alone
or stratified by donor gender. Red dots represent genes showing significantly different expression (FDR < 0.1). (c) Heatmap representing
hierarchical clustering of samples using Euclidean distances calculated from regularized log2 transformation to visualize samples with similar or
dissimilar characteristics in relation to analysed outcomes and perfusion status. (d) Gene signatures associated with DGF risk factors analysed
in the context of the whole transcriptome (TOM1, left panel) and after adjustment for BioAge (right panel). DBD: donation after brain death;
DCD: donation after cardiac death; ECD: extended criteria donor; SCD: standard criteria donor; CIT: cold ischaemia time; WIT: warm ischaemia
time (anastomosis time); R.gender: recipient gender; D.gender: donor gender
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and frequency of alternative splicing (AS) events. Alternative splicing
is a common post‐transcriptional modification that enables cells to
increase protein diversity from a single copy of a gene by generation
of unique coding transcripts or regulatory noncoding RNAs. These
can be affected by changes in DNA methylation status and GC con-
tent at the intron–exon boundaries, ultimately affecting both splicing
outcomes, alternative splicing networks and affecting writing and/or
maintenance of epigenetic marks and changes in chromatin status
(Francisco & Baralle, 2017; Shiran Naftelberg, Ast, & Kornblihtt,
2015). Transcripts associated with chromatin remodelling were sig-
nificantly affected by the perfusion status in our cohort and included
polycomb group genes (BMI1, SUZ12, TRIM27); chromobox/HP1
homologs (CBX4, CBX8); bromodomain proteins (BRD2, WDR11);
ING family members (ING1, INg2, ING4) and PHF21B.
DGF‐specific transcripts revealed differential promoter methyla-
tion status dependent upon perfusion state and DGF occurrence. An
increase in DNA methylation within the promoter and intragenic
regions of the respective DGF‐associated genes was observed for
IGF compared to DGF in preperfusion samples. This relationship was
lost, or reversed after reperfusion, suggesting that reperfusion can
directly and immediately affect epigenetic status in tissues. These
observations are supported by animal model studies where 30‐min
IRI was sufficient to affect global DNA methylation levels (Endres
et al., 2000; Meller, Pearson, & Simon, 2015).
A representative comparison between epigenetic status, RNAseq
and qPCR data is summarized in Supporting Information Figures S1
and S2 in Data S4. Interestingly, an increased incidence of AS events
was associated with reperfusion injury, but not DGF occurrence. No
AS events were detected in the DGF‐specific transcript set. The top
100 differentially expressed transcripts between perfusion states
were analysed, with only 42 displaying AS events, as indicated by
differential exon expression (Figure 3a,b, Supporting Information
Data S6). A representative example of an AS event has been illus-
trated using interferon regulatory factor 1 (IRF1) (Figure 3c,d). This is
suggestive of a complex relationship between methylation status and
alternative splicing associated with IRI injury that is not observed in
organs displaying DGF.
2.4 | Validation of DGF‐specific transcripts
Transcripts related to DGF, selected based on their ranking by statis-
tical significance of observed expression change and diversity of sig-
nalling pathway involvement in relation to publically available data
sets, were further validated in 19 paired biopsies from the RNAseq
cohort and an independent cohort of 32 pairs of samples. Three
samples were excluded from further analysis due to post‐transplant
complications. Nineteen genes were validated as markers of DGF.
Transcripts were further analysed in relation to donor character-
istics, ischaemic time and estimated glomerular filtration rate (eGFR/
MDRD4), as a measure of physiological function, at 3, 6 and
12 months post‐transplantation (Table 2). Interestingly, most of the
DGF‐specific transcripts that correlated positively with donor age
were negatively correlated with allograft performance after trans-
plantation, including PTPRC, SEMA3A, KLRB1, CD52, CCL19,
F IGURE 2 Gene signatures associated with DGF after adjustment for ischaemia reperfusion injury (TOM4) presented as heatmaps, left
panel (adjusted p‐value < 0.05). The expression counts were normalized by regularized log2 transformation. The phenotypic attributes
associated with samples are mapped at the top of the plot. Preperfusion samples (B), postperfusion samples (B1). The right panel consists of
top ranked DGF‐specific genes (adjusted p < 0.05) and the left panel consists of DGF signature after adjustment for BioAge. Two samples
were excluded from the further analysis as they did not pass QA and QC control before bioinformatics analysis (106B and 39B1). R.gender:
recipient gender; D.gender: donor gender; DGF: delayed graft function; IGF: immediate graft function
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LNRC4, GABBR1 and UBD. KLRB1 was a common denominator for
DGF, ECD status, DCD status and allograft performance, while
SEMA3A was differentially expressed in relation to DGF, ECD sta-
tus; Cr T1/2 and allograft function post‐transplant. FCGR1C was
related to DGF outcome, DCD status and allograft function.
Additionally, RNAscope was performed on 18 preperfusion biop-
sies from the RNAseq cohort for which tissue sections were available,
to confirm the presence of five selected transcripts namely CD45,
INFγ, ACKR3, SEMA3A, REG1B and PPIB as a positive control.
2.5 | Validation of DGF gene expression at the
protein level
The expression of DGF‐specific genes at the protein level was
undertaken using western blotting in a subset of samples to deter-
mine whether changes at the protein level could be related to DGF
and/or reperfusion injury (Supporting Information Data S7). Samples
were isolated sequentially from the same tissue specimen after RNA
and genomic DNA isolation and equal amount of total protein was
used in the further analysis. Eight DGF‐associated proteins were
detected. Four (FCGR1C, FCGR2C, CD52 and PTPRC) were not
detectable. Five genes associated with DGF were further validated
in the tissue biopsies to verify both their expression and localization
at the protein level in 18 preperfusion biopsies. Morphological and
histological analyses of these biopsies were undertaken for 17 histo-
logical variables associated with renal pathology (including CKD and
AKI) and assessed using several published histological scoring sys-
tems for kidney quality (Maryland Aggregate Pathology Index,
Chronic Allograft Damage Index, Banff Score and Remuzzi Score).
These revealed no obvious correlation between overall quality score
and the presence or absence of DGF. The expression of CD45, IFNγ,
REG1B or SEMA3A showed no significant differences in signal inten-
sity or location between biopsies from donor kidneys that would
experience IGF compared with those demonstrating DGF. ACKR3
expression was negative overall with the exception of two samples.
2.6 | DGF and perfusion status are associated with
cellular senescence
The expression of the CDKN2 locus in relation to the DGF outcome
and perfusion status at the transcript level, including CDKN2A/
p16INK4, ARF/p14, CDKN2B, as well as other senescence‐associated
markers (TP53, CDKN1A/p21 and CDKN1B/p27) was determined.
Significantly, higher expression of CDKN2B/p15 and CDKN1A
was noted in postperfusion biopsies compared to the preperfusion
biopsies (p = 0.0003 and p < 0.0001, respectively).
Furthermore, a positive relationship between CDKN2A/p16INK4
and TP53 in preperfusion biopsies (cc = 0.305; p = 0.039) was
observed; this correlation was lost after reperfusion. CDKN2A/
p16INK4 was positively correlated with ARF/p14 (cc = 0.48,
p = 0.000) and CDKN2B/p15 (cc = 0.405, p = 0.004) in preperfusion
biopsies, whereas ARF/p14 was correlated with CDKN2B (cc =
0.397, p = 0.004). CDKN2A/p16INK4 was correlated with donor age
(cc = 0.489; p = 0.000 and cc = 0.419, p = 0.002) and MDRD4 at
3 months (cc = −0.473; p = 0.001 and cc = −0.310, p = 0.030) and
6 months (cc = −0.471; p = 0.001 and cc = −0.397, p = 0.005) post‐
transplant regardless of the perfusion status. However, only preper-
fusion CDKN2A/p16INK4 was negatively correlated with MDRD4
F IGURE 3 Alternative splicing is associated with reperfusion injury. (a) MA plot representing differential exon expression between
preperfusion versus postperfusion samples. (b) Number of differentially expressed exons between perfusion states and number of alternatively
spliced genes selected from top 100 targets differentially expressed between perfusion states. (c) Differential exon expression in relation to
perfusion state for IRF1. (d) Hypothetical alternative transcript predicted for IRF1 (interferon regulatory factor 1).
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(cc = −0.393, p = 0.009). Interestingly, preperfusion TP53 expression
was correlated with CIT (cc = 0.406, p = 0.004), whereas postperfu-
sion TP53 expression was associated with MDRD4 at 12 months
(cc = −0.378; p = 0.014).
The expression of preperfusion CDKN1A was positively corre-
lated with CIT (cc = 0.347, p = 0.017), whereas serum creatinine at
12 months post‐transplant was positively correlated with postperfu-
sion expression of CDKN1B (cc = 0.333, p = 0.033) and CDKN1A
(cc = 0.344, p = 0.022). Additionally, preperfusion expression of
CDKN1B was associated with serum creatinine (cc = 0.432,
p = 0.003) and MDRD4 (cc = −0.346, p = 0.020) at 6 months post‐
transplant.
Four preperfusion biopsies from the RNAseq cohort were
selected to visualize histological differences in extreme DGF and IGF
outcomes between young (age 40–42) and old (age 74) donors and
were stained for CDKN2a/p16INK4 and γH2AFX (Figure 4).
Overall CDKN2a/p16INK4 positivity appears to be predominately
cytoplasmic, with greater positivity within distal tubular epithelium
versus proximal tubular epithelium across all samples and with proxi-
mal tubular epithelium showing greater positivity in older donors
compared to younger donors.
Overall, regardless of DGF/IGF status, positivity for γH2AFX
appeared to be predominately nuclear in tubular epithelial cells, at
least mild and more often in the distal tubules than the proximal
tubules. Interestingly, the subcellular localization of the γH2AFX
signal within arterial myocytes appeared to associate with donor age
more so than with immediate function status after transplantation, in
that biopsies from kidneys from younger donors showed more cyto-
plasmic than nuclear γH2AFX, with older kidneys showing greater
nuclear than cytoplasmic positivity in arterial myocytes.
3 | DISCUSSION
To our knowledge, this work is the first study in human subjects that
demonstrates a unique molecular signature for impaired physiological
resilience (DGF), encompassing epigenetic and transcriptomic data
sets. Critically, at a translational level, it also provides a platform for
the development of a universal IRI signature and the ability to relate
it to post‐transplant outcomes. This is also the first study linking
DNA methylation status to reperfusion injury and DGF outcome, in
the context of immune system status, overall dysregulation of cellu-
lar homeostasis and its consequences for allograft performance.
These data, together with the validation of DGF‐associated gene
products at the protein level, provide a unique and synchronous gen-
ome, transcriptome and proteome snapshot.
Our study provides strong evidence that biological age in combi-
nation with physiological stress, resulting from immune system acti-
vation and generation of inflammatory responses, plays a major role
in DGF occurrence and the physiological manifestations of IRI. From
a clinical perspective, this also suggests that these effects are driven
by donor characteristics, which may therefore be even more discrim-
inating than reperfusion injury itself. Correspondingly, BioAge in the
preperfusion biopsy analyses appeared to be a significant determi-
nant of post‐transplant allograft function, in keeping with previous
observations centring on the CDKN2 and CDKN1 loci (Gingell‐Little-
john et al., 2013; McGuinness et al., 2016). Furthermore, it suggests
strongly that increased allograft biological age is contributory to less
successful outcomes in renal transplantation and poorer post‐trans-
plant performance.
Activation of the immune system may be a prerequisite driver
for DGF occurrence, with the predicted top ranked upstream regula-
tors being associated with innate immune system activity. Upregula-
tion of transcription for UBD, NLRC4, IFNγ and IFNγ‐inducible
targets OAS2 and CXCL10 is congruent with a model of inflamma-
some activation leading to the recruitment of corresponding IFNγ
effector cells, represented by elevated transcriptional levels observed
for CD52, CD45, FCGR1C and KLRB1. These data suggest that ther-
apeutic intervention to modulate the innate immune pathway activa-
tion and related events would be expected to mitigate the effect of
IRI and reduce acute kidney injury during the peritransplantation
period. Furthermore, these observations are consistent with the the-
sis of inflammaging, whereby increased chronic inflammation may
hyperinflate biological ageing processes, thus causing more rapid
deterioration of organ function.
Three of the top five ranked DGF‐specific transcripts locate to
the major histocompatibility class 1 (HLA) locus. GABBR1 (6p22.1)
and ubiquitin D (UBD; 6p21.3) are located very close to the region
coding for HLA‐F (Fan et al., 1996), suggesting that this locus may
F IGURE 4 Immunohistochemical staining for γH2A (top panel)
and CDKN2AINK4 (bottom panel) on kidney biopsies form young and
old patients with IGF (immediate graft function) and DGF (delayed
graft function) outcomes, respectively. Sections were scanned at 20x
magnification. NC: negative control
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be of importance for the development of DGF and impairment of
physiological resilience. The third transcript, BTN3A2, originates
from the gene located in the juxta‐telomeric region of the HLA locus
and is involved in the adaptive immune response and inhibition of
INFγ release. GABBR1 has been associated with proteasome activa-
tion and cytoskeleton remodelling, with differential responses to IRI,
dependent upon severity of insult (Caldeira, Salazar, Curcio, Can-
zoniero, & Duarte, 2014). UBD has also previously been implicated
in renal pathology, via involvement in inflammatory‐mediated sig-
nalling and immune system modulation. UBD directs its substrates
for 26S proteasomal degradation (irreversible proteolysis) and accel-
erates autophagy in nutrient‐deprived conditions (Gong et al., 2010;
Schmidtke, Aichem, & Groettrup, 2014). This can be supported by
significant transcriptome changes associated with mitochondria and
mitochondrial energy metabolism (PMAIP1, SLC25A25, BBC3,
SH3GLB1,NEFL, SLC25A2, HSP90AA1, CPT1B, GADD45B, DNAJB1,
LRP5L, ARRDC3, HSPA1B, HSPA1A, EDN1) and autophagy
(MAP1LC3B, CXCR4, DAPK1, EIF2AK3, INFG, IGF1, PTEN, TNFα,
RB1, DRAM2, HSP90AA1).
The activation of the recipient immune system and downstream
signalling pathways may be superseded by the subsequent impact of
repair/regeneration pathways. It is possible that this inability to suffi-
ciently resolve inflammatory responses manifests as DGF and could
be attributed to a differential response to reperfusion injury by bio-
logically older allografts and decreased resilience to stress (Gingell‐
Littlejohn et al., 2013; McGuinness et al., 2016; O'Neill et al., 2015;
Salvadori, Rosso, & Bertoni, 2015). Such a scenario is supported by
the reperfusion signature associated with cellular events (metabolic
shift, autophagy, RNA metabolism, ribosomal biogenesis, protein
synthesis) activated in response to environmental stress (ischaemic
damage, nutrient deprivation and hypoxia), which facilitates cellular
repair after insult, or induces apoptosis if the damage is too severe.
Recent evidence has indicated that these prosurvival and repair
pathways associated with ageing are conserved across taxa, and
include the mTOR, AKT and p38 pathways, suggesting that insuffi-
cient resolution of the response to peritransplant stresses is associ-
ated with dysregulation of cellular homeostasis (Gingell‐Littlejohn
et al., 2013); Kennedy & Lamming, 2016; Figure 5). These pathways
are critical regulators of cellular metabolism allowing cells to sense
and adapt to environmental factors, with some being involved in the
regulation of lifespan in model organisms, including mTOR signalling.
Notably, sirolimus, a mTOR inhibitor, is already used as an immuno-
suppressant following renal transplantation. While use of sirolimus is
associated with reduced risk of malignancy in transplant recipients, it
also correlates with an increased risk of death when the allograft has
originated from a cadaveric donor. No such correlation, however,
has been observed from living donor allografts, supporting the cen-
tral role of mTOR signalling and associated pathways for the regula-
tion of cellular metabolism and health span (Knoll et al., 2014).
Our results are in keeping with recent studies linking organ bio-
logical age, as opposed to chronological age, to allograft performance
post‐transplant and overall kidney function (Gingell‐Littlejohn et al.,
2013; McGuinness et al., 2016). Increased biological age of renal
allografts can be associated with reduced functional/repair capacity
as a result of a greater degree of allostatic load/overload. This is
thought to contribute to the DGF phenotype, as a result of an inabil-
ity to restore physiological homeostasis in the face of peritransplant
stress and subsequent recipient immune challenge (Kooman et al.,
F IGURE 5 Proposed model for DGF
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2014). Our data are in keeping with such a scenario, with organs dis-
playing DGF also exhibiting a greater change in transcriptional ampli-
tude in DGF signature transcripts following transplantation and
requiring a longer period to restore physiological homeostasis, which
may be related to deficient proteostasis. These data indicate that
allografts exhibiting DGF may therefore be displaying features of
allostatic overload at a transcriptional level whose effects are extrap-
olated across the organ as a whole, resulting in functional impair-
ment (Kooman et al., 2014).
Analysis of transcript expression observed solely in DGF, but not
IGF, in relation to perfusion status, indicated a transcript biotype
shift (Supporting Information Table S1 in Data S8), including an
increase in antisense, pseudogenes, noncoding and coding RNAs, for
example immunoglobulin gene (IgV and IgV pseudogenes) and T‐cell
receptor (TR J) transcripts. These changes in the transcriptome bio-
types further support the hypothesis that the response to IRI, both
in magnitude and context, are dependent upon donor characteristics
and organ response/resilience to stress and may also reflect deregu-
lation of alternative splicing networks and epigenome status overall.
The biotype changes observed may reflect a burst of “transcriptional
noise” in DGF allografts in response to IRI, as a direct result of
changes in the methylation status of promoters and intragenic
regions (Huh, Zeng, Park, & Yi, 2013). These observations are also
consistent with the derepression of LINE elements in ageing cells
(De Cecco et al., 2013).
Immunological response to “danger signals” may lead to exces-
sive activation of proinflammatory cytokines and chemokines, conse-
quently leading to organ damage over time, as observed in the case
of autoimmune diseases, where there is a loss in ability to downreg-
ulate/attenuate proinflammatory signalling (de Jesus, Canna, Liu, &
Goldbach‐Mansky, 2015). This suggests that donor characteristics
are important for DGF occurrence and may be linked to organismal/
organ stress levels in relation to the type of organ donation (Bon
et al., 2012; Morrissey & Monaco, 2014). Ultimately, allograft quality
will be related to organ resilience to stress, and this by itself pro-
vides an opportunity for the development of new therapeutic inter-
ventions aimed at exploiting this phenomenon. Recent studies
focusing on the progression of chronic kidney disease (CKD) have
exemplified the importance of epigenetic changes and loss of kidney
function (Smyth, McKay, Maxwell, & McKnight, 2014; Wing et al.,
2014). Our data have indicated rapid changes in the epigenome dur-
ing perfusion, suggesting that the effect of IRI on long‐term allograft
function may be more pronounced than originally anticipated.
The lack of available models for DGF has meant that direct vali-
dation of targets and any related mechanism has not been possible.
To mitigate the impact of this shortfall, we have therefore used our
DGF transcriptomic signature to identify any commonality with other
renal/urological transcriptomic expression profiles derived from pub-
licly available data sets. These included renal interstitial fibrosis, kid-
ney transplant failure and rejection, kidney disease, nephrotic
syndrome, cystic disease of kidney and renal tubular disorder (Sup-
porting Information Data S3). Notably, the overlap identified encom-
passed transcripts involved in immune system activation, both
supporting the importance of interaction between lymphoid and
nonlymphoid cells in the context of renal function and highlighting
the biological plausibility of the DGF‐related findings.
Overall, our data suggest that allografts exhibiting DGF present
with an impaired ability to restore physiological homeostasis in
response to stress, consistent with their biological age and associ-
ated allostatic load. This is reflected in changes in epigenome, tran-
scriptome and dysregulation of RNA metabolism. The magnitude of
change in transcriptional amplitude in response to physiological
stress, along with elevated expression of noncoding RNAs and pseu-
dogenes, raises the possibility that reduction in available cellular
resources for activation of damage repair mechanisms slows down
physiological and cellular repair processes, resulting in long‐term
damage to the allograft (Figure 5).
4 | EXPERIMENTAL PROCEDURES
4.1 | Clinical cohort characteristics
Fifty‐five paired preperfusion and postperfusion renal biopsies col-
lected from deceased donors were included in this study, and all kid-
neys were subsequently transplanted with no occurrence of primary
nonfunction. Detailed patient characteristics and follow‐up markers
are described in Table 1. This study and consent procedure was
approved by the Regional Ethics Committee of North Glasgow NHS
Trust (GN10SU334, 10/S0704/42, NHS GG&C Biorepository −276
and 348). Donors from the national pool donated their organs for
transplantation. The recipient of the organ provided preoperative
written informed consent and records are stored at Queen Elizabeth
University Hospital (QEUH). From this cohort, 24 pairs of samples
defined as the extreme DGF phenotype or immediate graft function
were selected for further analysis (Figure 1a).
4.2 | Biopsy processing
Total RNA, genomic DNA and protein were sequentially isolated
from the same tissue biopsies using TRI®Reagent according to the
manufacturer's instructions (Invitrogen, UK).
4.2.1 | RNA isolation
Total RNA from kidney biopsies was extracted using TRI®Reagent
according to the manufacturer's instructions, DNase treated (RNA
Clean & Concentration, #R1015, Zymo Research, USA) and stored at
−80°C for further analysis. RNA underwent spectral analysis (A260/
280 nm) and determination of RIN number (RNA Nano kit and 2100
BioAnalyzer (#5067–1511, Agilent Technologies, Inc. USA). For fur-
ther analysis, samples with RIN>6.0 were used.
4.2.2 | RNAseq and data analysis
Libraries, from 400 ng total RNA, were created using ribosomal
depletion (n = 48, 24 paired biopsies; TruSeq Stranded Total RNA
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Ribo‐Zero H/M/R Gold, Illumina). Prepared libraries were assessed by
Qubit® (Life Technologies, Inc. USA) and Bioanalyser (High Sensitiv-
ity DNA kit [#5067–4626, Agilent Technologies, Inc., USA]). Libraries
were sequenced on a NextSeq500 (Illumina) using a paired‐end
75 × 75 bp run. The raw sequence reads in FASTQ format were fur-
ther analysed using the following pipeline: Initial QC for RNAseq
output was analysed using FastQC v.0.11.2 (https://www.bioinforma
tics.bbsrc.ac.uk/projects/fastqc), adapters were removed using trim_-
galore v.0.3.7 (https://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/). Three bases from the 3' end of all paired‐reads were
trimmed to avoid any biases related to adapter sequence or basecall
quality. Poor quality bases (phred score <20) were removed. Two
samples 39B1 and 106B were excluded from further analyses as
they failed QA and QC checks. The trimmed reads were mapped
against the reference human genome (GRCh38 from ensemble) using
Tophat v.2.0.13 (Kim et al., 2013). The annotation file (GRCh38
release 78 from Ensemble) was used for mapping of transcript anno-
tations. Mapped fragment counts were summarized using fea-
tureCounts with ensemble gene‐ids using subread v1.4.6 (Liao,
Smyth, & Shi, 2014). Differential gene expression (DGE) analysis was
performed using DESeq2 v1.6.3 (Love, Huber, & Anders, 2014). Raw
count data were transformed to log2 scale to normalize expression
counts. Multiple testing correction was performed using the Ben-
jamin–Hochberg approach to control false discovery rate (FDR) at
10% (FDR ≤ 0.1 was considered significant). Differentially expressed
gene targets were analysed using Ingenuity®Pathway Analysis
(IPA®, QIAGEN's, USA) and NextBio Research (Illumina, USA).
4.2.3 | Alternative splicing analysis
Alternative splicing events were investigated in the RNAseq cohort
(top 100 differentially expressed transcripts, pre vs. post) and DGF‐
specific transcripts identified by RNAseq using DEXSeqv1.16.10
(Anders, Reyes, & Huber, 2012). Differential exon usage (DEU),
followed by the application of generalized linear modelling, was used
to identify alternative splicing events (FDR < 0.1 was considered
significant).
4.2.4 | Whole genome bisulphite sequencing and
analysis
Genomic DNA was isolated from the same biopsy, using TRI®Rea-
gent, after separation of RNA into aqueous fraction and further puri-
fied (Genomic DNA Clean & Concentrator, Zymo Research, USA).
100 ng of genomic DNA was bisulphite converted using EZ DNA
Methylation‐GoldTM Kit (Zymo Research). Bisulphite‐converted geno-
mic DNA was used to generate indexed libraries using EpiGnomeTM-
Methyl‐Seq kit (Epicentre®Illumina) according to the manufacturer's
instruction. Library quality and quantity were assessed using DNA
High Sensitivity kit (Agilent Technologies, Inc. USA). Sample selection
for WGBS included 20 samples (10 matched pairs with five being
DGF and five IGF). The resulting 20 libraries were sequenced on a
NextSeq500 (Illumina) with 30× coverage, paired‐end run
(2 × 150 bp). The raw sequence reads in FASTQ format underwent
QC as previously described above. Sample 180b1 was excluded from
further analysis as it failed QA and QC.
The human reference genome (GRCh38) was in silico bisulphite
converted before aligning trimmed reads with Bismark v0.10.1 and
bowtie2 (v2.1.0) as previously described(Krueger & Andrews, 2011;
Langmead & Salzberg, 2012). PCR bias was removed by a deduplica-
tion step. The methylation content was measured on CpG context
sites of DGF‐specific targets. The promoter and intragenic regions
were extracted from biomart API (BiomaRt; Durinck, Spellman, Bir-
ney, & Huber, 2009), and differences within the methylated CpG
sites were further analysed using Kruskal–Wallis test. FDR correction
for multiple comparison was applied for all analyses. Adjusted p‐
value below 0.05 was considered as statistically significant.
4.2.5 | QPCR and data validation
For each individual RT reaction, 150 ng of total RNA from each sample
was used and reverse transcription was performed using SuperScrip-
t®II Reverse Transcriptase (# Life Technologies Inc., UK) and then
qPCR was performed. Gene expression was analysed using TaqMan®-
gene expression assays, or custom design assays using Roche UPL
(Supporting Information Data S9), which were normalized against
HPRT1 and 18S rRNA control primer sets. Taqman® assays, including
standards, were performed using the manufacturers recommended
qPCR protocols and TaqMan®Master Mix (#4370074, Life Technolo-
gies, UK). For UPL probes, primers were used at final concentration
360 nM while probes were used at final concentration of 100 nM.
The comparative threshold cycle method (ΔΔCT) was used to quantify
relative gene expression, and the obtained quantification was trans-
formed to exponential value 2−ΔΔCT. Commercially available RNA was
used as a calibrator (#AM7976, Life Technologies, Inc.). Further testing
involved Spearman correlations and Kruskal–Wallis test. FDR correc-
tion for multiple comparison was applied for all analyses. Adjusted p‐
value below 0.05 was considered as statistically significant.
4.2.6 | RNAscope
In situ hybridization detection for CD45 (601998), REG1B (312058),
INGγ (310508), SEMA3A (416568), ACKR3 (441458) and PPIB
(313908) mRNA was performed using RNAscope 2.5 LS (Brown)
detection kit (Advanced Cell Diagnostics, Hayward, CA) on a Leica
Bond Rx autostainer strictly according to the manufacturer's instruc-
tions. The analysis was performed using an established method at
the Histology Core in the Beatson Institute for Cancer Research,
Glasgow, UK.
4.2.7 | Western blot
Protein fractions were isolated from the phenol–ethanol fraction after
removal of genomic DNA (TRI®Reagent, Invitrogen, UK). Protein con-
centration was estimated using DCTMProtein assay (BioRad, UK), and
7.5 µg of total protein was loaded per well. Samples were resolved in
14 of 16 | MCGUINNESS ET AL.
4%–12% or 12% SDS‐PAGE in MOPS buffer using NuPAGE®System
(Life Technologies Inc., UK) and transferred onto the polyvinylidene
fluoride (PVDF) membrane. After immunoblotting, membranes were
washed in Tris‐buffered saline (TBS), blocked in 5% nonfat dry milk in
TBS‐0.1% Tween 20 (TBST) for 1 hr at room temperature, followed
by the incubation with primary antibodies in blocking solution over-
night at 4°C. After incubation, membranes were washed in TBST and
incubated with the goat antirabbit IgG (1:10,000; Cell Signalling,
#7074S) or goat antimouse IgG (1:5,000, Cell Signalling, #707) horse-
radish peroxidase (HRP)‐conjugated for 1 hr in room temperature.
The reaction was developed using Enhanced Chemiluminescence
(ECL) System (Life Technologies Inc.). The following primary antibod-
ies from Abcam (UK) were used: CHGB (1:4,000; ab151568), REG1B
(1:1,000; ab87205), Corin (1:500; ab56158), UBD (1:500, ab134077),
KLRB1 (1:500, ab197979), SEM3A (1:1,000, ab23393), ACKR3
(1:2,000), ZNF676 (1:500, ab179754), TAGAP (1:1,000, ab187664),
HPRT1 (1:10,000, ab109021), FCGR1C (ab119843), FCGR2C
(ab125013), CD52 (ab194860) and PTPRC (ab40763) and β‐tubulin/
HRP conjugated (1:2,000, ab20058, 2 hr at RT).
4.2.8 | Immunohistochemistry
The analysis was performed using an established automated method at
the Histology Core in the Beatson Institute for Cancer Research, Glas-
gow, UK. Heat‐induced antigen retrieval was performed using sodium
citrate retrieval buffer (pH = 6, Thermo, UK) at 98°C for 25 min fol-
lowed by peroxidase block (Dako, UK) for 5 min. The previously opti-
mized primary antibodies from Abcam: ACKR3 (ab72100, 1:500), INFγ
(ab9657, 1:500), SEMA3A (ab23393, 1:500) and CD45 (Dako, M0701,
1:1,000), REG1B (MyBiosource, MBS2025956, 1:500) and an appropri-
ate secondary antibody (EnVision, Dako, UK) were used. Staining and
counterstaining were performed using 3,3‐diaminobenzidine (DAB)
and haematoxylin, respectively. Previously validated CDKN2A/p16 (M‐
156‐sc759; 1:250; Santa Cruz Biotechnology Inc, USA) and γH2AFX
(ab81299, 1:1,000; Abcam, UK) antibodies were stained manually.
4.3 | Data and materials availability
RNAseq and WGBS data have been deposited at GEO repository with
reference no: GSE90865 for publication, and this includes subseries
GSE90861 and GSE90863. All relevant data are available upon request.
Data from this study are available from the senior author (PGS).
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